The observed effects of chronic pharmacologic blockade of GLUT proteins in two distinct murine models of cardiomyopathy provide novel insight into dynamic compensatory changes in glucose transporter biology and the role normal glucose homeostasis in the context of heart failure. Here, SLC2A1 is linked to cardiomyopathy.